Agents modulating beta-catenin functions and methods thereof

US11198713B2 · kind B2 · utility

Assignee

• FOG PHARMACEUTICALS, INC. · US

Inventors

• Gerard Hilinski · Somerville, US
• So Youn Shim · Watertown, US
• Matthew Reiser Patton · Cambridge, US
• John Hanney McGee · Palo Alto, US
• Paula Cristina Ortet · Malden, US
• Gregory L. Verdine · Boston, US

Key dates

• Filing date: Sep 7, 2018
• Grant date: Dec 14, 2021
• Expiry date: Sep 7, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K16/2827
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Among other things, the present disclosure provides technologies for modulating functions of beta-catenin. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin. In some embodiments, provided stapled peptides interact with beta-catenin at an Axin-binding site of beta-catenin. In some embodiments, the present disclosure provides compounds, compositions and methods for preventing and/or treating conditions, disorders and diseases that are associated with beta-catenin.